Clinical Research Directory
Browse clinical research sites, groups, and studies.
FINE-START: Efficacy and Safety of Finerenone in Patients With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
Sponsor: University Medical Center Groningen
Summary
Study to demonstrate efficacy of finerenone when compared to placebo in reducing albuminuria in participants with chronic kidney disease (CKD) not using renin-angiotensin-system (RAS) inhibitors.
Official title: A Parallel-group, Randomized, Prospective, Interventional, Double-blind, Multicenter Global Phase 3 Study to Investigate the Efficacy and Safety of Finerenone Versus Placebo, in Participants With Chronic Kidney Disease Not Using Renin-angiotensin-system Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
180
Start Date
2026-03-23
Completion Date
2027-12-31
Last Updated
2026-04-01
Healthy Volunteers
No
Conditions
Interventions
Finerenone (BAY 94-8862)
Finerenone 10 or 20mg in participants with chronic kidney disease not using renin-angiotensin-system inhibitors
Placebo
Placebo matching finerenone
Locations (8)
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Vall d'Hebron University Hospital
Barcelona, Spain
Clínica Universidad de Navarra
Madrid, Spain
Hospital Universitario de La Princesa
Madrid, Spain
Hospital Universitario Puerta de Hierro
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Hospital Universitario Dr Peset
Valencia, Spain